Kestra Medical Technologies director Ladone sells $98,464 of KMTS stock By Investing.com

Mary Kay Ladone, a director at Kestra Medical Technologies, Ltd. (), sold 3,908 common shares on September 8, 2026. The transactions totaled approximately $98,464, with shares sold at prices ranging from $24.9100 to $25.4300. The weighted average price for these sales was $25.1956. The stock has since declined to $23.57, down 8% over the past week, according to InvestingPro data. The timing comes just days before the company’s September 14 earnings report. InvestingPro analysis suggests the stock is currently overvalued relative to its Fair Value.

The sale was a nondiscretionary transaction, executed to satisfy tax withholding obligations related to the vesting and settlement of restricted stock units.

Separately, on September 9, 2026, Ms. Ladone acquired 7,217 restricted stock units. Each unit entitles her to receive one common share of Kestra Medical Technologies. These restricted stock units are scheduled to vest on September 9, 2027, contingent on her continued service to the company.

Following the sale, Ms. Ladone directly owns 37,507 common shares. This total includes 17,512 common shares received from West Affum Holdings, L.P., in a pro rata distribution. After the acquisition of the restricted stock units, her total beneficial ownership of Kestra Medical Technologies securities stands at 44,724 shares.

In other recent news, Kestra Medical Technologies reported a significant increase in revenue for the fiscal fourth quarter of 2026, with total revenue reaching $28.6 million. This marks a 66% year-over-year growth, exceeding the consensus estimate of $26.5 million. Despite the impressive revenue growth, the company reported an adjusted earnings per share loss of $0.67, which missed Wall Street’s forecast of a $0.58 loss. Analysts have been active in their assessments of Kestra Medical, with JPMorgan initiating coverage with an Overweight rating and a price target of $30.00, highlighting the potential of Kestra’s ASSURE wearable cardioverter-defibrillator. Oppenheimer started coverage with a Perform rating, noting the large addressable market and rising market share against the incumbent. Stifel reiterated a Buy rating, citing strong growth and maintaining a $30.00 price target. Wolfe Research also increased its price target to $30.00, maintaining an Outperform rating due to the company’s strong execution. These developments reflect a growing interest in Kestra Medical’s market potential and performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.